SummaryMiddle-aged Americans face worse health outcomes, including obesity, hypertension, and high cholesterol, than even disadvantaged Brits, highlighting disparities and the impact of limited healthcare access in the US.
SummaryWith FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.